NASDAQ · SNY
Healthcare · Drug Manufacturers - General
$42.40
Down-$0.93 (-2.15%)
Updated Sep 16, 2026, 11:03 AM
SID Score
6.2/10
Composite research score
Smart Money
54/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SNY closed at $42.40 after 20 trading sessions, down 5.71% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $42.78 | $42.89 | $42.38 | $42.40 | 2.68M |
| Sep 14, 2026 | $43.70 | $43.74 | $43.015 | $43.33 | 2.33M |
| Sep 11, 2026 | $42.81 | $42.885 | $42.41 | $42.77 | 2.37M |
| Sep 10, 2026 | $42.86 | $43.05 | $42.67 | $42.72 | 1.96M |
| Sep 9, 2026 | $43.08 | $43.46 | $42.8205 | $42.85 | 1.95M |
| Sep 8, 2026 | $43.49 | $43.71 | $43.14 | $43.155 | 2.6M |
| Sep 4, 2026 | $44.17 | $44.36 | $44.025 | $44.24 | 1.7M |
| Sep 3, 2026 | $45.15 | $45.16 | $44.20 | $44.33 | 2.4M |
| Sep 2, 2026 | $44.68 | $45.22 | $44.43 | $44.47 | 2.17M |
| Sep 1, 2026 | $45.08 | $45.23 | $44.205 | $44.37 | 2.02M |
| Aug 31, 2026 | $44.59 | $44.69 | $44.26 | $44.36 | 2.35M |
| Aug 28, 2026 | $44.93 | $44.96 | $44.65 | $44.82 | 1.36M |
| Aug 27, 2026 | $44.86 | $45.08 | $44.72 | $44.84 | 2.29M |
| Aug 26, 2026 | $46.01 | $46.04 | $45.39 | $45.42 | 1.63M |
| Aug 25, 2026 | $45.73 | $46.05 | $45.57 | $46.02 | 1.24M |
| Aug 24, 2026 | $45.49 | $45.78 | $45.32 | $45.69 | 1.72M |
| Aug 21, 2026 | $45.26 | $46.11 | $45.25 | $45.85 | 1.86M |
| Aug 20, 2026 | $45.65 | $45.74 | $45.06 | $45.15 | 2.6M |
| Aug 19, 2026 | $45.42 | $46.02 | $45.42 | $45.83 | 2.74M |
| Aug 18, 2026 | $45.10 | $45.22 | $44.735 | $44.97 | 3.17M |
The latest Smart Investors Daily articles mentioning SNY.
SNY research
Company profile and research snapshot.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 14, 2026 | TD COWEN | Hold | — |
| Jul 13, 2026 | ROTHSCHILD & CO REDBURN | Neutral | — |
| Jul 12, 2026 | DAY BY DAY | Sell | — |
| Jul 8, 2026 | BANCO SANTANDER | Outperform | — |
| Jul 1, 2026 | JEFFERIES | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 12, 2026
Regeneron Pharmaceuticals (NASDAQ:REGN) executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo investor conference appearance. Ryan Crowe, senior vice president of investor relations and strategic ana
Yahoo · Sep 11, 2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,415,546,786Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regis
Yahoo · Sep 10, 2026
Opportunities include deeper uptake in refractory chronic GvHD, expansion across Europe and Asia, broader pediatric access through an oral suspension, and potential use in lung transplant rejection and other fibrotic or immune-mediated diseases.Dublin, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The "REZUROCK Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. REZUROCK (belumosudil) continues to strengthen its position in the chronic graft-versus-host dis
Yahoo · Sep 9, 2026
LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SNY.
